Traders should monitor for downward price pressure and potential negative catalysts; such concentrated selling by top executives, especially the CEO and R&D lead, often precedes disappointing developments in clinical-stage biotechs. Consider hedging long positions or reducing exposure ahead of upcoming data readouts or earnings.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 12 $80.32entry
- T+1 · 8mo ago −3.06%α −2.47% · $77.86
- T+5 · 8mo ago −0.40%α +0.58% · $80.00
- T+20 · 7mo ago +11.77%α +9.79% · $89.77
- T+60 · 5mo ago +0.24%α −10.46% · $80.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dianthus Therapeutics CEO, R&D head, and CFO-equivalent executed a coordinated cluster of derivative exercises and open-market sales over a 7-day window, realizing $7.5M in proceeds. The transactions include both non-cash exercises and direct sales at prices between $80.70 and $81.48, with the CEO and CFO selling over $4.7M and $1.2M respectively.
Key Financial Metrics
Key Facts
- CEO Garcia Marino sold $3.51M in shares and exercised derivatives for 182,618 shares (partially non-cash), realizing $1.22M in cost basis.
- EVP Randhawa Simrat sold $2.76M and exercised derivatives for 15,996 shares with $67,503 in cost basis.
- Chief Accounting Officer Carr sold $1.28M and exercised 16,182 shares with $289,334 in cost basis.
- Total open-market sales: $7.5M across 3 insiders on March 12, coinciding with peak stock price activity.
- All sales occurred within a 4-day window at prices near $81, representing a coordinated liquidity event.
Financial Impact
$7.5M in insider sales over 7 days, representing 0.21% of $3.5B market cap, significant for a biotech of this size.
Risk Factors
- Insider selling may signal lack of confidence in near-term clinical or financing outcomes.
- Potential for follow-on dilution given cashout of executives ahead of possible capital raise.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (11 trades, 7d window) | cluster-DNTH-1773782600349 |
Track record
23 reports on DNTH
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +41.40% at T+60 after the Jun 11, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $89.76 Now $89.55 −0.23% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $88.81 to $89.30 Now $89.55 +0.83% ▲ +0.55% −0.77% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $83.01 to $86.03 Now $89.55 +7.88% ▲ +3.64% +3.33% vs SPY
- Oct 30, 202617d ago Institutional Cluster Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $82.38 to $82.25 Now $89.55 +8.70% ▼ −0.16% +0.32% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $81.57 to $77.58 Now $89.55 +9.78% ▼ −4.89% −4.88% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 4/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 3/10 Entry $112.41 to $109.60 Now $89.55 −20.34% ▼ −2.50% −3.20% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers